Purpose: e purpose of the present study was to evaluate the e ects of di erent loading doses of clopidogrel on ST segment resolution on ECG, changes in cardiac enzyme levels and serum levels of high-sensitivity C-reactive protein (Hs-CRP) in patients with ST elevated myocardial infarction (STEMI) treated with brinolytic therapy.
Clopidogrel with 300 mg loading dose and followed by 75 mg maintainance dose is advised in ST elevated myocardial infarction (STEMI) patients who are under 75 years and treated with brinolytic therapy [1, 2] . E ect of high dose clopidogrel loading in patients with STEMI treated with primary angioplasty was evaluated well previously and 600 mg loading dose was found to be more e ective; however, e ects of high loading doses of clopidogrel in STEMI patients treated with brinolytic therapy have not yet been studied thoroughly.
e aim of our study was to determine the e ects of di erent additional loading doses of clopidogrel on ST-segment resolution on ECG, serum levels of cardiac enzymes and highsensitivity C-reactive protein (Hs-CRP) in STEMI patients who received brinolytic therapy.
Methods

Patient Population
Patients who presented with ischemic discomfort lasting >20 minutes at rest within 12 hours with ST-segment elevation of at least 0.2 mV in at least two contiguous precordial leads were enrolled. e study was limited to only anteriorly located myocardial infarction to homogenize the investigated population.
e exclusion criteria were conduction or rhythm abnormalities (bundle branch block, idioventricular rhythm, etc.), any contraindication to thrombolytics, early coronary angiography due to recurrent ischemia or failed thrombolysis, those on aspirin and/or thienopyridines treatments, any contraindication to aspirin or clopidogrel, past history of MI or coronary revascularization; presence of heart failure (Killip class II/III) or cardiogenic shock, hepatic failure, renal failure (serum creatinine >2.5 mg/dL), thrombocytopenia (<100.000/mm ) and patients older than 70 years. Major bleeding was de ned as intracranial bleeding or clinically overt bleeding associated with a decrease in hemoglobin of >5 g/dl according to the TIMI criteria [3] . e study protocol was approved by the institutional review board, and written informed consent was taken from all patients.
Study Protocol
A total of 180 patients were included initially in the study. e rst 60 consecutive patients were allocated to Group 1, the second 60 consecutive patients were allocated to Group 2 and the last 60 consecutive patients were allocated to Group 3. Two patients in Group 1, ve patients in Group 2 and one patient in Group 3 were excluded because of recurrent ischemia. Physicians performing the follow-up assessment were not aware of the group assignment. Standard protocol for reperfusion therapy was a 300 mg loading dose of aspirin followed by 150 mg/ day, unfractionated heparin 60 U/kg i.v. bolus (maximum 4000 U) followed by an infusion at 12 U/kg/h (maximum 1000 U/h), administration of tissue plasminogen activator (tPA) with 15 mg i.v. bolus followed by 0.75 mg/kg infusion during rst 30 minutes and then 0.5 mg/kg infusion during 60 minutes (maximum100 mg). In addition, Group 1 patients (n=55) received a loading dose of 300 mg clopidogrel and a maintenance dose of 75 mg/d clopidogrel, Group 2 (n=58) received a 450 mg loading dose and a 75 mg/d maintenance dose and Group 3 (n=59) received a 600 mg loading dose and a 75 mg/d maintenance dose. Di erent loading doses of clopidogrel were given at the time of randomization in the emergency department before sending patient to coronary care unit.
Blood Measurements
Blood samples were taken from le antecubital vein from all patients. All collected blood samples were analysed by OLUMPUS AU 600 and Bayer Advia 120 Cell CBC Counter Hematologia. Routine biochemical parameters (glucose, lipid pro le, urea and creatinine) and complete blood counts (hemoglobin, hematocrite and leucocytes) were analyzed daily. Baseline and 48 hour hs-CRP levels were measured by a high sensitivity nephelometric method. Determined values were recorded separately for each patient.
ECG Analysis
Standard 12-lead electrocardiograms (ECG) were obtained at baseline and at 30 minute periods during the rst 120 minutes a er initiation of brinolytic therapy with an ECG recorder (Nihon Kohden, Tokyo, Japan). ST-segment elevation was analyzed manually with lens-intensi ed calipers to the nearest of 0.025 mV at 20 milliseconds a er the end of QRS complex with the PR segment as the reference baseline from leads I, aVL, and V1 through V6 for anterior infarction. e percent resolution of ST deviation from baseline to 30, 60, 90 and 120 minutes was calculated. More than 50 % resolution in ST segment elevation was accepted as a succesful criteria for reperfusion.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows square tests for categorical variables. One-way anova and post hoc Bonferroni test were used for continuous variables between study groups. Results were presented as 95% con dence intervals and statistical signi cance was accepted as p value less than 0.05.
Results
ere was no statistically signi cant di erence among all three groups with regards to demographic characteristics and baseline laboratory parameters (p>0.05) ( Table I ). CK and CK-MB levels at 0, 4 and 8 hour periods were similar in all groups (p>0.05). Peak levels of CK and CK-MB levels were reached at 8 hour in Group 3 while peak levels of cardiac enzymes were reached at 12 hour in Group 1 and Group 2. In addition, peak levels of cardiac enzymes were lower in Group 3 than in Group 1 and 2. ere was a statistically signi cant di erence between Group 1 and Group 3 in CK and CK-MB levels at 12, 16, 20 and 24 hours. While CK-MB levels were signi cantly di erent in Group 2 and 3 at 12, 16, 20 and 24 hours; CK levels were signi cantly di erent only at 12 and 16 hours (p<0.05) ( Table  2) . e times required for complete resolution of ST-segment elevation were compared between groups: while ST resolution was completed at 30 minutes in more than half (58%) of Group 3 patients to whom 600 mg clopidogrel were given, it was completed in Group 2 at 60 minutes and Group 1 at 90 minutes. Consequently, there existed a signi cant di erence between groups in terms of ST resolution periods (p<0.05) ( Table 3) . In other words, earliest ST resolution was achieved in Group 3 patients to whom a loading dose of 600 mg clopidogrel was given, then in Group 2 patients to whom a loading dose of 450 mg was given and lastly in Group 1 patients to whom a loading dose of 300 mg was given (Table 3) . Although baseline hs-CRP levels between groups were similar, a signi cant di erence was found at 48 hours. As the loading dose of clopidogrel increased, the peak levels of hs-CRP decreased (dose-related inverse relationship) and this difference was statistically signi cant among all three groups (p<0.001) ( Table 4) .
Major hemorrhagic complication occured in only one patient in Group 1 as a central nervous system hemorrhage.
One patient in both Group 1 and Group 2 had a small hematoma in the upper extremity and one patient in Group 3 had a epistaxis that was managed by local pressure.
Discussion
In this study, the e ects of 450 mg and 600 mg clopidogrel loading doses were determined. ese doses are above the guidelines, which advise a 300 mg loading dose. e e ects of high loading doses on ST resolution, changes in enzymes and serum levels of an in ammatory parameter such as hs-CRP were also investigated. According to our data, increased loading dose of clopidogrel provided earlier ST resolution in ECG, earlier and lower peak cardiac enzyme levels and lower serum hs-CRP levels. In the COMMIT study, which included 45852 STEMI patients treated with brinolytics and anticoagulants, aspirin and aspirin plus clopidogrel were compared. In that study, a 9% decrease in primary end points and a 7% decrease in mortality rates were found in clopidogrel group at the end of one month [4] . ere was no clopidogrel loading dose in the COMMIT study. In addition, short-and long-term bene cial e ects of loading doses on reperfusion in acute coronary syndromes and reductions in reinfarctions and mortality rates were reported in studies evaluating clopidogrel loading doses. In the CLARITY-TIMI 28 trial, STEMI patients treated with brinolytic therapy were randomized to either a 300 mg loading dose plus 75 mg daily clopidogrel or a placebo. When the data was evaluated a er 48-192 hours, the investigators reported that reinfarction, death rate, TIMI 0 and TIMI 1 rates were lower in clopidogrel group [5] . Also in the ECG CLARITY-TIMI 28 trial, it was shown that the rate of ST segment resolution was signi cantly higher in the group to which clopidogrel was given [6] .
Previous studies investigated the e ects of high doses of clopidogrel (i.e.,450 and 600 mg) in STEMI patients treated by primary angioplasty (PTCA) and they reported that higher doses had positive e ects [7, 8] . But studies evaluating the effects of higher doses of clopidogrel on STEMI treated with brinolytic therapy are limited. there are no other studies in literature comparing 300 mg loading dose of clopidogrel with higher loading doses.
Although previous studies reported bene cial e ects of 450 and 600 mg clopidogrel loading doses on STEMI treated by primary PTCA, there was no additional bene t when loading dose was increased to 900 mg. For this reason, in our study, subjects were given 450 mg and 600 mg loading doses.
No group was evaluated for 900 mg loading dose for ethical reasons. In the ARMYDA-2 trial, it was reported that 600 mg clopidogrel loading dose resulted in an earlier and more potent inhibition of ADP -induced platelet activation than 300 mg loading dose without a signi cant side e ect and hemorrhage in STEMI patients undergoing primary coronary artery stenting [7] . Similarly, in the ISAR-CHOICE study, antiplatelet and pharmacokinetic e ects of di erent clopidogrel doses were compared and it was reported that 600 mg clopidogrel loading dose provided a higher plasma concentration and more platelet inhibition than 300 mg loading dose, while increasing the loading dose to 900 mg did not make any di erence [8] .
Previous studies reported that STEMI patients with successful reperfusion had lower peak CK and CK-MB levels, shorter time to achieve peak enzymes values and, consequently, shorter time needed for the normalization of these cardiac enzymes when compared with unsuccessful reperfusion in STEMI [9, 10] . In our study, peak CK and CK-MB levels were lower in Group 3 and time to achieve peak enzymes levels was shorter than for other groups.
It was thought that as the relation between atherosclerosis and in ammation was de ned clearly, the in ammatory markers in circulation could help determining cardiovascular event risk. In comparison with other in ammatory markers, the role of CRP in determining the risk of cardiovascular disease stands out [11] . e results, which are numerous, broad, randomized and prospective in method, make us believe that basic hs-CRP levels can be used to determine future cardiovascular risk [12] [13] [14] . It has already been proven that hs-CRP levels have a prognostic value for patients with acute coronary syndrome, in the short as well as in the long term [15, 16] . Clopidogrel, as a platelet ADP P2-Y12 receptor antagonist, was investigated in numerous studies for its anti-in ammatory properties in addition to its antithrombocyte e ects. A study by Zairis et al., which included 319 patients admitted with STEMI and then treated with trombolytic therapy, reported that the group with higher CRP levels had a igni cantly lower incidence of STsegment resolution and higher of in-hospital mortality rate [17] .
Study Limitations
e most important limitations of our study are the small patient population and absence of a sophisticated randomization protocol. Although our patient population was large enough to detect the positive e ects of clopidogrel, it was inadequate to detect possible hemorrhagic complications. Another limitation of our study is that coronary reperfusion a er brinolytic therapy was not assessed with coronary angiography. Other limitations of our study include the limited (48 hour) follow-up period, the inclusion of patients presenting only with anterior STEMI, the use of only t-PA as thrombolytic therapy and absence of clinical endpoints.
Conclusion
In the present study, with three di erent loading doses of clopidogrel, the higher dose was found to provide more e - cient reperfusion and anti-in ammatory e ects. Based on these results, the 600 mg loading dose of clopidogrel, which is the maximum dose used in our study, should yield more favorable results for both reperfusion and treatment of in ammation. Large scale studies with longer follow-up periods are needed to understand the e ciency of clopidogrel loading doses higher than 300 mg in STEMI patients treated with brinolytic therapy andour study is important to encourage these larger studies.
